Consultation outcome

Consultation questions

Updated 31 January 2023

Question 1

Do you support proposal 1, to apply a 10% indexation uplift across Agency statutory fees to match the increased pay costs national average since the last MHRA fees review?

Question 2

Do you support proposal 2, to place a cost-based uplift for 61 significantly under recovering fees to achieve full cost recovery?

Question 3

Do you support proposal 3 to introduce 22 new fees for services offered by the MHRA?

Question 4

Would you consider these proposals to impact certain types of business disproportionately? e.g. small businesses?

Question 5

Do you think any of the proposals in this consultation could have an impact on the development and access to medicines or devices for (1) rare conditions or (2) minority groups with smaller patient populations?

Question 6

Do you think any of the proposals in this consultation pose a risk to existing products being withdrawn from the UK market?

Question 7

Do you think any of the proposals in this consultation could have an impact on research, clinical trials or clinical investigations in the UK?

Question 8

With reference to the protected characteristics covered by the Public Sector Equality Duty set out in section 149 of the Equality Act 2010 or by section 75 of the Northern Ireland Act 1998, we do not consider that our proposals risk impacting different people differently with reference to their protected characteristics. Do you agree?

Question 9

In Northern Ireland new policies must be screened under Section 75 of the Northern Ireland Act 1998 which requires public authorities to have due regard to rural needs.

We do not consider that our proposals risk impacting different people differently with reference to their protected characteristics or where they live in Northern Ireland. Do you agree? Yes/No.